Results 251 to 260 of about 284,370 (314)
Breast cancer surgery increasingly favors nipple‐sparing and endoscopic techniques to optimize oncological safety, cosmetic outcomes, and patient satisfaction. We aimed to evaluate and compare the clinical efficacy and postoperative safety profiles of endoscope‐assisted and conventional open approaches for nipple‐sparing mastectomy with immediate ...
Yuan Shao +6 more
wiley +1 more source
International comparisons of survival after recurrent metastatic breast cancer in four countries: A population-based study. [PDF]
Fink H +13 more
europepmc +1 more source
A total of 556 patients were included in the analyses. Most patients (88%) received primary treatment aligned with the MDT's recommendations. The highest level of concordance was seen in those with early breast cancer who were recommended to have primary surgery (94%), and the lowest in those with metastatic disease.
Nerushka Naidoo +5 more
wiley +1 more source
Increased treatment options and improved survival in real-world patients with HER2-positive advanced gastric cancer from 2011 to 2023. [PDF]
Shimozaki K +12 more
europepmc +1 more source
Read the free Plain Language Summary for this article on the Journal blog. Abstract In the context of anthropogenic eutrophication of the biosphere, understanding the impact of nutrient addition on plant diversity–productivity relationships remains a major challenge.
Dai F. Saito +7 more
wiley +1 more source
Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du +3 more
wiley +1 more source
SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial. [PDF]
Yao H +31 more
europepmc +1 more source
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue +5 more
wiley +1 more source
Quantitative MRI mapping parameters to differentiate HER2-positive and HER2-low breast cancer. [PDF]
Zhang Y +8 more
europepmc +1 more source

